LEEM

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

Retrieved on: 
Thursday, April 25, 2024
ISS, LEEM, CSR, Research, Gold, Patient, Classification, Executive Committee, Social responsibility, Ethics, Disclosure, Pharmaceutical industry

Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 Extra-Financial Performance Report (fiscal year 2023).

Key Points: 
  • Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 Extra-Financial Performance Report (fiscal year 2023).
  • The Company is also preparing for the application of new or draft European standards relating to non-financial disclosures.1 The 2024 report (fiscal year 2023) is available on GENFIT 's website.
  • This social impact fund has been awarded the "Relance" label and is a candidate for the "Socially Responsible Investment" label.
  • Regarding our ambitious 2023 roadmap, we have successfully executed this in alignment with the plan crafted by the ESG Committee.

Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech

Retrieved on: 
Tuesday, April 2, 2024
Other Health, Research, General Health, Oncology, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Partner (business rank), France Biotech, Patient, Cancer, LEEM, Imagination, Creativity, Merck Group, IQVIA, Multimedia, Pharma, Pharmaceutical industry

Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .

Key Points: 
  • Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .
  • The ceremony took place on Monday, March 25th in Paris, gathering key players in the French health innovation ecosystem.
  • (France Biotech Press Release)
    This award testifies to the relevance of Brenus Pharma's mission: to restore the ability of cancer patients to fight resistant tumor cells and avoid relapses like never before.
  • Finally, congratulations to all the winning startups, nominees, and others who thrive and provide daily efforts for the health of patients."

Brenus Pharma Announces its Strategic Committee Supporting & Ensuring Its Value-creating Strategic Plan

Retrieved on: 
Wednesday, March 1, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, LEEM, CDMO, Strategy, Society, Trust, HEC Paris, Doctor, Immune system, GE HealthCare, MBA, CSL Vifor, Paris, Non-executive director, Patient, CanSino Biologics, STC, Doctor of Pharmacy, CSO, Roche, Education, Fine chemical, Management, Pharmaceutical industry, Vaccine, Takeda

BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.

Key Points: 
  • BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.
  • Pierre MORGON (Pharm D, LL.M, MBA): CEO, MRGN Advisors ; Executive VP, CanSino Biologics; Board chairman and non-Executive director, several biotech.
  • “We are delighted to have top renowned healthcare industry executives at our side to challenge and support our strategic plan and are thankful for their trust.
  • Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment.